Clinical Trials Logo

Herpes Zoster clinical trials

View clinical trials related to Herpes Zoster.

Filter by:

NCT ID: NCT04188327 Recruiting - Pain Clinical Trials

Stellate Ganglion Block in Herpes Zoster

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Patient who will be presented to Tanta University Hospitals complaining of acute herpes zoster with onset of vesicular eruption less than 7 days will be included in this clinical study. Patients will be excluded if they refused participation, had allergy to local anesthetics, coagulopathy, local infection, glaucoma, or neurological deficit. All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the patients will be classified into two groups:- Group I (control group): Patients will receive sham block weekly for three times Group III (SGB group): Patients will receive stellate ganglion block weekly for three times The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of complication will be measured.

NCT ID: NCT04006808 Recruiting - Herpes Zoster Clinical Trials

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Start date: October 25, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

NCT ID: NCT03509701 Recruiting - Clinical trials for Reversible Cerebral Vasoconstriction Syndrome

Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus

RCVS&VZV
Start date: May 1, 2018
Phase:
Study type: Observational

Among patients with thunderclap headache who were admitted to the four participating hospitals, who has diffuse segmental vasoconstriction on CT angiography or MR angiography will be eligible for the study. Participants who meet the definition of RCVS will be enrolled as the case-patients and others will be enrolled as control-patients. The RCVS group will be defined when two or more neurologists agree by the clinical features and angiographic findings. The result of tests for varicella zoster virus titer will not be opened to neurologists until the end of the study. For case and control patients, tests for varicella zoster virus infection are (1) Pre-existing virological markers (ex. VZV-IgG, IgM, and VZV PCR in CSF or Skin lesion if present) (2) VZV-specific cell mediated immune response (CMI) at the time of admission and one month later (3) VZV in blood measured by quantitative test of viral load with real-time PCR and digital PCR for latent viral load (4) Quantitative test of viral load with real-time PCR in saliva at time of admission and one month later. Reactivation or infection of VZV of patients with RCVS and controls will be compared.

NCT ID: NCT03178747 Recruiting - Herpes Zoster Clinical Trials

Tzanck Smear With Methylene Blue Stain for Herpes

Start date: March 7, 2017
Phase: Phase 3
Study type: Interventional

To compare the sensitivity of Tzanck smear with methylene blue stain versus traditional Giemsa stain in patients with herpes infection.

NCT ID: NCT02689700 Recruiting - Clinical trials for Materno-fetal Transfer of Anti-VZV-IgG

Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns

MoChi-HCMV
Start date: July 2013
Phase: N/A
Study type: Observational

The aim of the study is to determine the total concentration of HCMV- and VZV-specific IgG-antibodies and the total concentration of neutralizing antibodies against HCMV in neonatal bloodstream depending on gestational age at birth.

NCT ID: NCT01866566 Recruiting - Varicella Clinical Trials

The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination

Start date: June 2013
Phase: Phase 4
Study type: Interventional

Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune procedure we could supply scientific and practical evidence for this two doses immune procedure promotion and management.

NCT ID: NCT01601925 Recruiting - Herpes Zoster Clinical Trials

Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block

Start date: January 2012
Phase: N/A
Study type: Interventional

Stellate ganglion block targets are C6 transverse process or C7 transverse process in anterior paratracheal approach which is most popular method. Cricoid cartilage is known that it is located at C6 level in supine neutral position of the neck. But stellate ganglion block is performed in supine extended position of the neck. So cricoid cartilage will move up to cephalad direction and pain doctors should find C6 or C7 transverse process at lower neck area than cricoid cartilage.

NCT ID: NCT01166295 Recruiting - Herpes Zoster Clinical Trials

Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia

BSTK
Start date: July 2010
Phase: N/A
Study type: Observational

Post herpetic neuralgia (PHN) is an undertreated condition. It is a type of neuropathic pain (NP), or pain caused by abnormal activity of sensory nerves. Its mechanisms are not fully understood, and medication trials for PHN pain and other types of NP are frequently unsuccessful. There has been extensive investigation aimed at identifying and understanding the specific mechanisms of NP. While some of these tests are inexpensive and easy to perform at the bedside, many require expensive tools and highly equipped laboratory facilities. Further, there is no standard method for assessment of pain in NP patients. The investigators aim to test a Bedside Sensory Testing Kit (assessment for Neuropathic Pain) on a small number of patients with PHN. The purpose of the Kit is to identify mechanisms of pain. The goal of this research is to design a way to classify patients with PHN based on what mechanisms are causing their pain, since this may help predict the best medications for individual patients.

NCT ID: NCT00492739 Recruiting - Immunosuppression Clinical Trials

Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients

VZVinOLTx
Start date: June 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. Furthermore, protection due to naturally acquired immunity to VZV or post-immunization isn't well described in this population.The questions asked are: - What is the influence of the immunosuppression required after orthotopic liver transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type varicella infection before OLT transplantation? - What is the influence of the immunosuppression required after OLT on VZV-specific immunity elicited by varicella immunization before OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the induction of VZV-specific B and T cell responses elicited by VZV vaccination after OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the persistence / waning of B and T cell responses elicited by VZV vaccination?

NCT ID: NCT00422539 Recruiting - Clinical trials for Atrophic Varicella Scar

Efficacy of TCA Effect on Varicella Atrophic Scars

Start date: March 2006
Phase: Phase 2
Study type: Interventional

This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella